Peter Ping Lin
Overview
Explore the profile of Peter Ping Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Nong J, Lu B, Gao Y, Hu M, Chen C, et al.
J Natl Cancer Cent
. 2024 Dec;
4(4):335-345.
PMID: 39735446
Background: Small cell lung cancer (SCLC) is a highly aggressive disease characterized by early metastasis. Aneuploid CD31 disseminated tumor cells (DTCs) and CD31 disseminated tumor endothelial cells (DTECs) residing in...
2.
Fu Z, Zhang L, Chen R, Zhan J, Zhong J, Zheng W, et al.
Cancer Lett
. 2024 Jul;
598:217099.
PMID: 38971491
An optimum safety excision margin (EM) delineated by precise demarcation of field cancerization along with reliable biomarkers that enable predicting and timely evaluating patients' response to immunotherapy significantly impact effective...
3.
Sun Q, Li W, Yang D, Lin P, Zhang L, Guo H
Arch Pathol Lab Med
. 2024 Apr;
149(1):39-49.
PMID: 38631685
Context.—: Most patients with non-small cell lung cancers (NSCLC) are diagnosed at advanced stages. The 5-year survival rate of patients with advanced lung cancer is less than 20%, which makes...
4.
Li S, Luo S, Wei N, Lin A, Wang D, Lin P, et al.
Oral Oncol
. 2023 Nov;
147:106602.
PMID: 37944219
No abstract available.
5.
Wang Y, Zhang L, Tan J, Zhang Z, Liu Y, Hu X, et al.
Cancer Lett
. 2023 Aug;
571:216337.
PMID: 37553013
Current management of small cell lung cancer (SCLC) remains challenging. Effective biomarkers are needed to subdivide patients presenting distinct treatment response and clinical outcomes. An understanding of heterogeneous phenotypes of...
6.
Wang Y, Liu Y, Zhang Z, Lu B, Gao Y, Tong L, et al.
BMC Cancer
. 2023 Jun;
23(1):578.
PMID: 37349714
Purpose: This study aimed to investigate the clinical utility of diverse aneuploid circulating tumor cell (CTC) subtypes and particularly CTC-associated white blood cell (CTC-WBC) clusters in predicting treatment response, prognosis...
7.
Mi J, Yang F, Liu J, Liu M, Lin A, Wang D, et al.
Front Oncol
. 2022 Sep;
12:981907.
PMID: 36172149
Effectively evaluating therapeutic efficacy, detecting minimal residual disease (MRD) after therapy completion, and predicting early occurrence of malignancy in cancer patients remain as unmet imperative clinical demands. This article presents...
8.
Li M, Gao F, Ren X, Dong G, Chen H, Lin A, et al.
Cancer Sci
. 2022 Aug;
113(10):3535-3546.
PMID: 35940591
Aneuploidy is the hallmark of malignancy. Our previous study successfully detected nonhematogenic circulating aneuploidy cells (CACs) in types of gliomas. The current prospective clinical study aims to further precisely subcategorize...
9.
Li Z, Fan L, Wu Y, Niu Y, Zhang X, Wang B, et al.
J Thorac Dis
. 2022 Jun;
14(5):1544-1555.
PMID: 35693614
Background: Recently, circulating tumor-cell-associated white blood cell (CTC-WBC) clusters have been reported to have prognostic value in some cancers. The prognostic role of CTC-WBC clusters in lung cancer has not...
10.
Huang M, Ma Y, Lv C, Li S, Lu F, Zhang S, et al.
Int J Gen Med
. 2021 Oct;
14:6609-6620.
PMID: 34703281
Purpose: This study aimed to explore the potential application of circulating tumor cells (CTCs) in predicting the therapeutic effect of neoadjuvant chemotherapy (NAC) in non-small-cell lung cancer (NSCLC). Methods: Using...